Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Front-line Ibrutinib Plus Rituximab in Unfit Patients With CLL
NCT02232386Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Mar 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in chronic lymphocytic leukemia (CLL), sponsored by GIMEMA. Primary endpoint: Progression-Free Survival at 12 months. Started Mar 2015; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02232386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02232386.